Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to ...

Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer. Adding immunotherapy to platinum-based chemotherapy is an established standard of care for ...

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma. The U.S.

NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

The U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation for iopofosine-131 in inoperable relapsed or refractory pediatric high-grade glioma (pHGG), according to a news ...

Keros Therapeutics (NASDAQ:KROS) sees unusual trading activity, driving attention in Nasdaq futures and top healthcare stocks ...

The European Commission’s approvals of TEVIMBRA in lung cancer are based on five randomized Phase 3 studies from the RATIONALE program. At ESMO 2025, BeOne will present new data from two of these ...

The upcoming presentations will showcase progress from HCB101, including both the HCB101-101 monotherapy (NCT05892718) and the HCB101-201 combination (NCT06771622) studies, as well as the preclinical ...

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...